Metis Global Partners LLC Sells 14,081 Shares of Edwards Lifesciences Corporation $EW

Metis Global Partners LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 30.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 32,437 shares of the medical research company’s stock after selling 14,081 shares during the period. Metis Global Partners LLC’s holdings in Edwards Lifesciences were worth $2,537,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $266,000. Allworth Financial LP grew its position in shares of Edwards Lifesciences by 6.3% during the 1st quarter. Allworth Financial LP now owns 3,513 shares of the medical research company’s stock worth $264,000 after buying an additional 208 shares during the period. Alps Advisors Inc. bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $369,000. Cerity Partners LLC raised its position in shares of Edwards Lifesciences by 67.9% in the 1st quarter. Cerity Partners LLC now owns 212,923 shares of the medical research company’s stock valued at $15,433,000 after acquiring an additional 86,089 shares during the period. Finally, Arizona State Retirement System boosted its stake in Edwards Lifesciences by 0.8% during the 1st quarter. Arizona State Retirement System now owns 173,090 shares of the medical research company’s stock worth $12,546,000 after acquiring an additional 1,363 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $83.37 on Monday. The company has a market capitalization of $48.38 billion, a price-to-earnings ratio of 12.00, a P/E/G ratio of 3.97 and a beta of 1.03. The business’s 50-day moving average price is $77.78 and its two-hundred day moving average price is $77.41. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $87.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on EW. Truist Financial upped their target price on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the company a “hold” rating in a research note on Monday, November 3rd. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Morgan Stanley lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. raised their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.